This review is devoted to the pathogenetic basis and clinical results of the use of a new domestic innovative drug Vesusten, which is based on polypeptides made of animal bladder tissue, for the treatment of patients with overactive bladder. Data are given regarding the epidemiology, pathogenesis factors and current treatment methods. The mechanisms of peptide regulation of physiological processes in humans are also described. The basic principles of the use of bioregulatory peptides for therapeutic purposes. The results of preclinical and clinical studies of the drug Vesusten are discussed in detail.

Keywords: bioregulatory therapy, Vesusten, detrusor overactivity, regulatory peptides, overactive bladder